Response after single treatment with canakinumab predicts which patients will benefit most

A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American Heart Association Scientific Sessions, Paul M. Ridker, MD, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, presented a pre-specified analysis on CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) that identifies a simple, clinical method to define patient groups most likely to benefit from long-term canakinumab treatment. The results of this analysis, published simultaneously in The Lancet, could have a major impact not only on patient selection and cost-effectiveness of canakinumab, but also on the future development of anti-inflammatory agents for cardiovascular disease.

Response after single treatment with canakinumab predicts which patients will benefit most

A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American ...

Mon 13 Nov 17 from Medical Xpress

Response after single treatment with canakinumab predicts which patients will benefit most, Mon 13 Nov 17 from Eurekalert

Novartis launches heart drug counter-offensive

ZURICH (Reuters) - Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors ...

Mon 13 Nov 17 from Reuters

AHA: CANTOS Substudy Supports Major Role Of Inflammation

(MedPage Today) -- Large reductions in hsCRP appeared to foretell improved outcomes

Mon 13 Nov 17 from MedPageToday

  • Pages: 1

Bookmark

Bookmark and Share